ClinicalTrials.gg
CompletedNCT01759030BIORAUpdated Mar 27, 2017

Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis

A Phase 3 interventional study of Rituximab in Rheumatoid Arthritis, sponsored by Biocad. Completed at 40 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-27.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Enrollment
30th of 63
181 · median 159
Started
2012
with 5 others
Phase 3
27 of 63
1 open now
Registered
41st of 63
by date
Lead sponsor
2 of 63
Biocad

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 30th largest by enrollment, is one of 6 that started in 2012, is one of 27 in phase 3, and was the 41st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis

Read the detailed description

This is an international multicenter double-blind randomized clinical study of the efficacy and safety (Phase III) with an active comparator; the study provides the additional evaluation of the interchangeability of rituximab biosimilar and original product MabThera.

The study will include 308 subjects with active seropositive rheumatoid arthritis who had intolerance or inadequate response to current therapy regimens including one or more TNF inhibitors, or who had contraindications to TNF inhibitors.

The first 24-week stage includes one course of rituximab therapy. The first study stage proposes central randomization into 2 large groups (1:1): patients from the first group will recieve BCD-020 (rituximab manufactured by CJSC BIOCAD) at a dose 1000 mg in a drop-wise manner on day 1 and day 15; patients from the second group will recieve MabThera at a same regimen.

On the final visit of Stage 1 (visit 11 at week 24) all efficacy parameters must be evaluated. If the disease activity remains (DAS28 score ≥2.6 or increased by 0.6 points or more compared to the last measurement) the patient will recieve another course of rituximab treatment. In this case a partial crossover (Stage 2) will take place (by means of the second randomization): one half of patients with active RA, previously treated with BCD-020, will receive MabThera at a dose 1000 mg on day 1 and day 15; and one half of patients with active RA, previously treated with MabThera, will receive BCD-020 at a dose 1000 mg ion day 1 and day 15. After the first rituximab infusion performed for retreatment, the patient will undergo 24-week follow-up (counted starting from the date of retreatment initiation). Thus, effects of the switch from BCD-020 to MabThera and vice versa will be assessed in 24 weeks after the crossover (Stage 2 of the study).

Patients in whom remission of RA (DAS28 \< 2.6) is reported on week 24 counting from the initial randomization will undergo the follow up for the next 24 weeks. During this period they will attend 3 visits (weeks 32, 40 and 48) in order to monitor the disease. If the exacerbation occurs within the time period not corresponding to week 32 or week 40, the patient will be invited to the study site for an out-of-schedule visit. If disease exacerbation is confirmed, he/she undergoes the second randomization, second rituximab treatment course and further follow up for 6 months (as described above).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis, DMARDs
  • rituximab
  • biosimilar
  • interchangeability
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having signed a written form.
  • Patients must be from 18 to 80 years of age (both ages inclusive)
  • Rheumatoid arthritis confirmed according to ACR 1987 criteria.
  • Seropositive rheumatoid arthritis.
  • Active rheumatoid arthritis during the last 3 months.
  • Disease score according to DAS28 of 3.2 or more, TJC≥8 (68), SJC≥8 (66), hsCRP≥6 mg/l, ESR≥28 mm/hr (by Westergren) at the moment of screening.
  • Patient's functional status - class I-III according to ACR classification
  • Inadequate response to DMARDs that include one or more TNF inhibitors, intolerance or to TNF inhibitors.
  • Necessity of methotrexate treatment during the last 4 weeks prior to screening period with stable/consistent dosage of 7.5 - 20 mg per week.
  • Patient's ability (in Investigator's opinion) to follow the protocol procedures;
  • Willingness to use during all study period.

Exclusion criteria

Exclusion Criteria:

  • Patients with Felty's syndrome (irrespectively to clinical form).
  • Patient's functional status - class IV according to ACR classification .
  • Rheumatoid arthritis low activity (less than 3.2 according to DAS28).
  • Concomitant therapy:

    • Previous treatment with any biological drug products causing CD20+ lymphocyte depletion, including biological drugs.
    • Treatment with azathioprine within 28 days before the study initiation and with leflunomide within 8 weeks before the study's principal phase (treatment with rituximab).
    • Intra-articular glucocorticosteroids within 4 weeks before the study's principal phase (treatment with rituximab).
    • Necessity for prednisone or its equivalent administration at dose more than 10 mg per day.
    • Necessity for prednisone or its equivalent administration at dose ≤10 mg per day in cases when this dose wasn't stable/consistent during last 4 weeks.
    • Necessity for administration of non-steroidal anti-inflammatory drugs for arthritis treatment in cases when its doses were not stable/consistent during last 4 weeks.
  • Pregnancy and breast-feeding.
  • Changes of laboratory values:

    • level is less than 100 g/l;
    • Leucocyte level is less than 3,0×10e9/l;
    • is less than 1,5×10e9/l;
    • level is less than 100×10e9/l.
  • Confirmed chicken pox within 30 days before inclusion to the screening.
  • Confirmed herpes zoster infection.
  • Acute forms of any infectious diseases, history of chronic infections with severe clinical manifestations.
  • Active tuberculosis, history of latent tuberculosis.
  • Inflammatory disease of the joints (present or in anamnesis) not related to rheumatoid arthritis (including gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease and others) or other systemic disease (including systemic lupus erythematosus, Crohn's disease, ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed forms of connective tissue inflammatory diseases, cross-syndrome and others).
  • Juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis developed before the age of 16.
  • Any determined immunodeficiency.
  • Pernicious anemia.
  • Confirmed cobalamine deficiency.
  • Other somatic diseases (apart from rheumatoid arthritis) that can increase the probability of adverse events during the study or can influence the estimation of symptom manifestation of RA ; mask, enhance or alter the symptoms of RA or cause clinical or laboratory symptoms similar to that of RA;
  • Positive results of serological test of surface antigen (HbsAg) or presence of Hbc IgM together with positive results of HBV PCR test, presence of antibodies to virus, syphilis or .
  • Major surgery within 28 days prior to the trial principal phase (treatment with rituximab).
  • Any mental disorder, including major depression and/or suicidal thoughts in anamnesis that can, in Investigator's opinion, create a risk for the patient or influence the patient's ability to follow the study protocol.
  • Unstable angina pectoris.
  • Myocardial infarction within less than 1 year prior to participation in the study.
  • Severe central or peripheral nervous system diseases.
  • Drug addiction, alcoholism.
  • Known to murine proteins or any other components of the medications used in the treatment, methotrexate, folic acid and any drugs used in premedication.
  • Presence of malignant neoplasm, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ and any with complete remission of more than 5 years;
  • Simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation; previous participation in this study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
181 participants (actual)

Study arms

  • Active comparator
    MabThera (F. Hoffmann-La Roche Ltd.)

    Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15). Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15). MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage).

    Drug: Rituximab

  • Experimental
    BCD-020 (CJSC BIOCAD)

    Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15). Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15. MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage).

    Drug: Rituximab

Interventions

  • Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).

    Also known as: MabThera, Rituxan, BCD-020

06

What researchers measure

Primary outcomes

  1. Number of patients who have reached ACR20 within 24 weeks after the treatment initiation

    Time frame: week 24

Secondary outcomes

  1. Frequency of adverse events (AE) and serious adverse events (SAE) that is related, in Investigator's opinion, to rheumatoid arthritis therapy

    Time frame: during all time of participation in the study

  2. Frequency of AE and SAE grade 3-4 that is related, in Investigator's opinion, to rheumatoid arthritis therapy

    Time frame: during all time of participation in the study

  3. Number of cases of early withdrawal from the study caused by AE or SAE

    Time frame: during all time of participation in the study

  4. Level of binding and neutralizing antibodies to rituximab in patients from both groups

    Time frame: at screening, week 12, week 24

  5. CD19+ and CD20+ lymphocyte counts

    Time frame: before infusion, after the 1st and the 2nd infusion of rituximab, on day 3,17,29 after the 1st infusion, at week 12,24,48

Other outcomes

  1. CD3+ lymphocyte count

    Time frame: before infusion, after the 1st and the 2nd infusion of rituximab, on day 3,17,29, at week 12,24,48

  2. Number of patients in each group who have reached ACR20

    Time frame: week 48

  3. Number of patients in each group that have reached ACR50/70

    Time frame: week 24, week 48

  4. Number of patients in each group with low RA activity according to DAS28

    Time frame: week 24, week 48

  5. Number of patients in each group with RA remission according to DAS28

    Time frame: week 24, week 48

  6. Number of patients in each group with RA remission according to ACR/EULAR

    Time frame: week 24, week 48

  7. X-ray characteristic of the involved joints

    1. Rate of progression in structural joint damage in Total Modified Sharp Score (erosion score, joint space narrowing score); 2. Percentage of patients without radiologic progression (by Steinbrocker).

    Time frame: week 24, week 48

  8. Functional ability index according to HAQ

    Time frame: week 12, week 24, week 48

  9. Quality of life assessment by SF-36 questionnaire

    Time frame: week 12, week 24, week 48

  10. Level of hsCRP and ESR by Westergren

    Time frame: Day 29, weeks 8,12,16,20,24,32,40,48

  11. Serum levels of IgA, IgG, IgM

    Time frame: Day 17,29, 46 weeks 24,48

  12. Serum level of rituximab

    Time frame: 0 h, 3 h, 6 h after infusion, on day 3 (48 h after the 1st infusion), day 17 (48 hours after the 2nd infusion), day 29 (after 336 hours after the 2nd infusion) and day 46 (744 hours after the 2nd infusion)

  13. Hazard ratio for the absence of remission according to DAS28 after 24 weeks from the switching from MabThera to BCD-020, comparing to the patients, which were retreated with MabThera without the switching to BCD-020

    Time frame: 48 weeks

  14. Hazard ratio for the absence of remission according to DAS28 after 24 weeks from the switching from BCD-020 to MabThera, comparing to the patients, which were retreated with BCD-020 without the switching to MabThera

    Time frame: 48

  15. Percentage of patients in each group that have reached ACR20/50/70 within 24 weeks after the retreatment initiation

    Time frame: 48 weeks

  16. Percentage of patients in each group with low RA activity according to DAS28 (2.6-3.2) in 24 weeks after the retreatment initiation

    Time frame: 48 weeks

  17. Percentage of patients in each group with RA remission according to DAS28 (<2.6) in 24 weeks after the retreatment initiation

    Time frame: 48 weeks

  18. Percentage of patients in each group with RA remission according to ACR/EULAR 2011 in 24 weeks after the retreatment initiation

    Time frame: 48 weeks

  19. Radiography characteristic of the involved joints after 24 weeks from the retreatment initiation including

    Time frame: 48 weeks

  20. Functional disability index according to HAQ-DI after 24 weeks from the start of retreatment

    Time frame: 48 weeks

  21. Quality of life assessment by SF-36 questionnaire after 24 weeks from the start of retreatment

    Time frame: 48 weeks

  22. Percentage of patients in each group withf binding and neutralizing antibodies to rituximab at screening, at week 12 an week 24 after the first infusion during the first cycle of therapy and after 24 weeks from the start of retreatment

    Time frame: 48 weeks

  23. Mean titre of binding and neutralizing antibodies to rituximab at screening, at week 12 and week 24 after the first infusion during the first cycle of therapy and after 24 weeks from the start of retreatment

    Time frame: 48 weeks

  24. Hazard ratio of any AE, that is related, in Investigator's opinion, to the use of rituximab and which has occurred after the switching from MabThera to BCD-020, in comparison with patients who were retreated with MabThera without switching to BCD-020

    Time frame: 48 weeks

07

Study locations

40 sites
  • Gomel Regional Clinical Hospital
    Gomel, Belarus
  • City Clinical Hospital №1
    Minsk, Belarus
  • City Clinical Hospital №9
    Minsk, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, Belarus
  • Satellite Orthopaedic Hospital & Research Centre Pvt Ltd
    Ahmadabad, India
  • Smt NHL Medical College and SethVS General Hospital
    Ahmadabad, India
  • Government Medical College and Hospital Panchakki Road
    Aurangabad, India
  • Bangalore Medical College and Research Institute, Victoria Hospital
    Bangalore, India
  • Pristine Hospital and Research Center Pvt. Ltd
    Bangalore, India
  • Sapthagiri Institute of Medical Sciences and Research Centre#15
    Bangalore, India
  • Sri Venkateshwara Hospital
    Bangalore, India
  • Sri Ramachandra Medical Centre, No.1
    Chennai, India
  • Swami Vivekananda National Institrute of Rehabilitation Training and research
    Cuttack, India
  • Gandhi Hospital, Department of Orthopedics
    Hyderabad, India
  • Sri Sri Holistic Hospitals
    Hyderabad, India
  • Sumana Hospitals, Research Department
    Hyderabad, India
  • Yashoda Hospital
    Hyderabad, India
  • Jaipur Hospital, Lal Kothi, Near SMS Stadium
    Jaipur, India
  • SMS Medical College & Hospital
    Jaipur, India
  • Calcutta national medical college, Kolkata
    Kolkata, India
  • Bhatia Hospital, Medical Research Society
    Mumbai, India
  • Government Medical College and Hospital
    Nagpur, India
  • Jawarlal Institute of Postgraduation Medical Education and Research
    Puducherry, India
  • B.J Medical college Sassoon General Hospital, Near Pune Railway Station
    Pune, India
  • Medipoint Hospitals Pvt Ltd
    Pune, India
  • Ruby Hall Clinic
    Pune, India
  • Christian Medical College
    Vellore, India
  • Chelyabinsk Regional Clinical hospital
    Chelyabinsk, Russian Federation
  • Clinical Hospital at Chelyabinsk Railway Station
    Chelyabinsk, Russian Federation
  • Kursk regional hospital
    Kursk, Russian Federation
  • Research Institute of Rheumotology
    Moscow, Russian Federation
  • Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko
    N.Novgorod, Russian Federation
  • Limited liability company Consultation and Diagnostic Center "Zdorovyye sustavy"
    Novosibirsk, Russian Federation
  • Local hospital at the station Smolensk OAO RZD
    Smolensk, Russian Federation
  • Smolensk State Medical Academy
    Smolensk, Russian Federation
  • North-Western State Medical University n.a. I.I.Mechnikov
    St.Petersburg, Russian Federation
  • Novgorod regional clinical hospital
    Velikiy Novgorod, Russian Federation
  • Kharkiv City Clinical Emergency Hospital n.a. O.I.Meschaninov
    Kharkiv, Ukraine
  • National Research Center "Cardiology Institute n.a. M.D.Strazheska"
    Kyiv, Ukraine
  • Odessa Regional Cardiology Dispensary
    Odessa, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2012
First posted
Jan 2, 2013
Start
Dec 2012
Primary completionActual
Jul 2015
CompletionActual
Jul 2015
Last update
Mar 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01759030
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Jan 2, 2013
Start date
Dec 2012
Primary completion
Jul 2015
Completion
Jul 2015
Last update
Mar 27, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion